Phio Pharmaceuticals Corp. (PHIO)

NASDAQ: PHIO · IEX Real-Time Price · USD
0.711
0.003 (0.49%)
At close: May 16, 2022 3:59 PM
0.710
-0.001 (-0.155%)
After-hours:May 16, 2022 7:31 PM EDT
Market Cap9.71M
Revenue (ttm)n/a
Net Income (ttm)-12.52M
Shares Out13.66M
EPS (ttm)-1.04
PE Ration/a
Forward PE3.01
Dividendn/a
Ex-Dividend Daten/a
Volume3,406,422
Open0.709
Previous Close0.708
Day's Range0.650 - 0.753
52-Week Range0.620 - 2.470
Beta1.83
AnalystsBuy
Price Target6.12 (+760.8%)
Earnings DateMay 12, 2022

About PHIO

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that t...

IndustryBiotechnology
CEOGerrit Dispersyn
Employees12
Stock ExchangeNASDAQ
Ticker SymbolPHIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for PHIO stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 760.76% from the latest price.

Price Target
$6.12
(760.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022

MARLBOROUGH, Mass. , May 16, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietar...

15 hours ago - PRNewsWire

Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment Expect to finalize IND-enabling studies for PH-894 in the second half of 2022 MARLBOROUGH, Mass. , May ...

4 days ago - PRNewsWire

Phio Pharmaceuticals Announces Senior Leadership Personnel Change

MARLBOROUGH, Mass. , May 5, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary...

1 week ago - PRNewsWire

Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022

MARLBOROUGH, Mass. , May 3, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary...

1 week ago - PRNewsWire

Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022

Marlborough, Mass., May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary ...

2 weeks ago - PRNewsWire

Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors

MARLBOROUGH, Mass. , May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary...

2 weeks ago - PRNewsWire

Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma

MARLBOROUGH, Mass. , April 26, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its propriet...

2 weeks ago - PRNewsWire

Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunothera...

MARLBOROUGH, Mass. , April 18, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its propriet...

4 weeks ago - PRNewsWire

3 Penny Stocks to Watch as Phio Pharma (PHIO) Explodes

Check these three penny stocks out as PHIO stock climbs The post 3 Penny Stocks to Watch as Phio Pharma (PHIO) Explodes  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks....

Other symbols:PTERIG
1 month ago - PennyStocks

Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation

Phio Pharmaceuticals Corp (NASDAQ: PHIO) has presented new preclinical data for PH-894, a self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4) The preclinical data exhibit...

1 month ago - Benzinga

Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractor...

MARLBOROUGH, Mass. , April 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprieta...

1 month ago - PRNewsWire

Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update

Company transitioning into a clinical stage company with start of the first clinical study for lead program, PH-762. MARLBOROUGH, Mass.

1 month ago - PRNewsWire

Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022

MARLBOROUGH, Mass., March 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietar...

2 months ago - PRNewsWire

Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2

MARLBOROUGH, Mass., Feb. 22, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical-stage biotechnology company developing the next generation of therapeutics based on its proprietar...

2 months ago - PRNewsWire

3 Hot Penny Stocks: Why TLOFF, PHIO and SBEV Are Seeing Big Gains Today

We're seeing major movement from some hot penny stocks today and are diving into all the recent news that has them on the rise! The post 3 Hot Penny Stocks: Why TLOFF, PHIO and SBEV Are Seeing Big Gains...

Other symbols:TSLA
4 months ago - InvestorPlace

French Regulatory Authority Gives Green Signal To Phio Pharma's Melanoma Trial

The French National Agency for the Safety of Medicines and Health Products has signed off Phio Pharmaceuticals Corp's (NASDAQ: PHIO) clinical trial with its lead product candidate, PH-762 in melanoma. T...

4 months ago - Benzinga

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma

MARLBOROUGH, Mass., Jan. 11, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...

4 months ago - PRNewsWire

Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual BioConnect 2022 Conference

MARLBOROUGH, Mass., Jan. 3, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...

4 months ago - PRNewsWire

Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy at the SITC 36...

MARLBOROUGH, Mass., Nov. 12, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...

6 months ago - PRNewsWire

Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

MARLBOROUGH, Mass., Nov. 10, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...

6 months ago - PRNewsWire

Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting

MARLBOROUGH, Mass., Oct. 18, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprieta...

6 months ago - PRNewsWire

Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and C...

MARLBOROUGH, Mass., Oct. 7, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietar...

7 months ago - PRNewsWire

Phio Pharmaceuticals Announces Two Upcoming Data Presentations at Scientific Conferences in October 2021

MARLBOROUGH, Mass., Sept. 30, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propriet...

7 months ago - PRNewsWire

Phio Pharma Shares Are Moving Higher On INTASYL Preclinical Data At ESMO Presentation

Phio Pharmaceuticals Corp (NASDAQ: PHIO) has announced preclinical results from a new study of a self-delivering RNAi (INTASYL) therapeutic platform. The data were presented at the European Society of M...

8 months ago - Benzinga

Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Target...

MARLBOROUGH, Mass., Sept. 16, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its propriet...

8 months ago - PRNewsWire